Think early.
Think BENLYSTA.

For patients with lupus, add BENLYSTA after hydroxychloroquine*

See the effect of BENLYSTA + ST vs placebo + ST on SRI-4 at Week 52. Effects on disease activity were primarily related to the most commonly involved organ systems.

See pivotal trial data

BENLYSTA + ST was evaluated in a real-world analysis of organ damage progression

* As part of standard therapy.

Think early.
Think BENLYSTA.

For patients with lupus, add BENLYSTA after hydroxychloroquine*

See the effect of BENLYSTA + ST vs placebo + ST on SRI-4 at Week 52. Effects on disease activity were primarily related to the most commonly involved organ systems.

* As part of standard therapy.

#1 prescribed biologic for lupus and lupus nephritis

† Source: IQVIA – National Prescription Audit – Total Dispensed Rx’s (NPAs TRx); Calendar Years 2019 – 2023.
SLE = Systemic Lupus Erythematosus; SRI = SLE responder index; ST = standard therapy.

† Source: IQVIA – National Prescription Audit – Total Dispensed Rx’s (NPAs TRx); Calendar Years 2019 – 2023.

SLE = Systemic Lupus Erythematosus; SRI = SLE responder index; ST = standard therapy.

Icon: Inflammation in multiple organ systems

Symptoms

Can BENLYSTA help manage your patient’s lupus symptoms?

Icon: Steroids

Steroids

Can BENLYSTA help your patients reduce their steroid dose?

Icon: Renal

Organ damage

Can BENLYSTA help slow organ damage progression for your patients?

In clinical trials, BENLYSTA was proven to reduce lupus symptoms in patients with lupus

Up to 61%

of patients had reduced disease activity (SRI-4) at Week 521-3‡

For patients with lupus nephritis, add BENLYSTA as part of initial therapy

In a clinical trial, BENLYSTA was proven to improve complete renal response in patients with lupus nephritis

74%

more likely to achieve complete renal response (renal remission) (secondary endpoint)4,5
(OR=1.74; 95% CI: 1.11, 2.74; P=0.0167)

More patients on BENLYSTA + ST (n=223) vs placebo + ST (n=223) achieved CRR at Week 104; 30% vs 20%, respectively.

Renal remission is defined here as complete renal response (CRR) and was a secondary endpoint in the 104-week BLISS-LN study.5

Primary endpoint: significantly more BENLYSTA patients (n=223) achieved renal response vs placebo (n=223); 43% vs 32%, respectively (P=0.0311).4

‡ SRI-4 response rate at Week 52 (primary endpoint).
BLISS-LN = Belimumab International Study in Lupus Nephritis; CI = confidence interval; CRR = complete renal response; OR = odds ratio..

BENLYSTA is recommended by EULAR and KDIGO as a treatment option for lupus and lupus nephritis6,7

EULAR = European Alliance of Associations for Rheumatology; KDIGO = Kidney Disease Improving Global Outcomes.

Well-established safety profile based on the largest clinical trial program in lupus and lupus nephritis

7000+

patients with lupus have been included in trials of BENLYSTA, including a clinical trial in patients with lupus nephritis (N=448)1-3,5,8-10

Why BENLYSTA?

Take a minute to listen to Dr. Alvin Wells, Rheumatologist, on why he prescribes BENLYSTA for his appropriate patients.

Paid consultant to GSK at the time of filming.

video transcript

ON-SCREEN TEXT: “Why BENLYSTA?”
Stay tuned for Important Product Information

ON-SCREEN TEXT: Dr. Alvin Wells, Rheumatologist
Paid consultant to GSK at the time of filming.

DR WELLS: Many of my rheumatology colleagues ask me all the time, “Why BENLYSTA?” I always tell them to take a step back and think about where we are in treating any patient in medicine now. We should be trying to use, to the best of our ability, evidence-based medicine.

ON-SCREEN TEXT: “Evidence-based medicine”

DR WELLS: And what does “evidence-based medicine” look like? It means that we have taken clinical trial data from randomized, placebo-controlled trials, data from peer-reviewed journals, and data that has been approved by the FDA to treat our patients. And fast forward, that’s where we are in using BENLYSTA in our patients with lupus.

ON-SCREEN TEXT: “Approved by the FDA”

DR WELLS: I also remind them and say when BENLYSTA was approved, we hadn’t had a drug for a number of years in treating patients with lupus. Before this, we had had drugs we kind of had borrowed and stolen from other specialties like oncology, drugs that go back into the 50s and into the 60s.

DR WELLS: So, when BENLYSTA came out, and remember this drug was designed to treat lupus, and targeting the underlying disease activity, the mechanism of action really kind of drives home that and that improvement that we see in our patients.

ON-SCREEN TEXT: BENLYSTA targets underlying disease activity

DR WELLS: So overall we talk about BENLYSTA, a drug that is designed specifically for disease activity in patients with lupus, a drug that has been FDA approved, that has a wealth of data around it, BENLYSTA has been a significant component of my armamentarium in treating patients with lupus disease activity.

ON-SCREEN TEXT: “BENLYSTA has been a significant component of my armamentarium”

ON-SCREEN TEXT: BENLYSTAHCP.com

DR. WELLS: Thank you for watching. Visit the BENLYSTA website for more information.

ON-SCREEN BUTTON: Visit the website

VOICEOVER:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis. Not for use in severe active central nervous system lupus. Reported: serious & sometimes fatal infections; progressive multifocal leukoencephalopathy; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

ON-SCREEN TEXT:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5+ with active SLE or active lupus nephritis. Not for use in severe active CNS lupus. Reported: serious & sometimes fatal infections; PML; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

ON-SCREEN TEXT:
BENLYSTA
(belimumab)
Intravenous Use 120 mg/vial
Subcutaneous Use 200 mg/mL

GSK Logo

Trademarks are owned by or licensed to the GSK group of companies.
©2022 GSK or licensor. BELVID220045 August 2022 Produced in USA.

Learn more

How to start a patient on BENLYSTA

BENLYSTA Gateway can help you and your patients access BENLYSTA.

Find out more

Peer perspectives

See what your peers have to say about their experience with BENLYSTA.

Find out more

Add BENLYSTA for your patients with lupus

Add BENLYSTA for your patients with lupus